Silver Book

Silver Book Fact

Reduction in hospital-acquired HAIs could produce significant savings

Practices that lead to a 20% reduction in preventable hospital-acquired HAIs would save up to $6.8 billion in medical costs. a 70% reduction would lead to a savings of up to $31.5 billion.

Scott, R. Douglas. The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention. Atlanta, GA: Centers for Disease Control & Prevention; 2009. http://www.cdc.gov/hai/pdfs/hai/scott_costpaper.pdf

Reference

Title
The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention
Publisher
Centers for Disease Control & Prevention
Publication Date
2009
Authors
Scott, R. Douglas
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Publications

Healthcare-Associated Infections Factsheet

 https://www.silverbook.org/wp-content/uploads/2015/06/Screen-Shot-2015-06-30-at-3.02.28-PM.png Thumbnail

Related Facts

  • Over 8 years infection control practices saved ~27,000 lives and $1.8 billion
    Infection control practices saved an estimated 27,000 lives and $1.8 billion in medical costs between 2001 and 2009.  
  • New antibacterial agents between 1983 and 2012
    Total number of new antibacterial agents is in decline  
  • Reduction of central-line infections saved ~ 1,800 lives and $280 million
    Standardization of best practice interventions reduced central line-associated blood stream infections and saved an estimated 1,800 lives and $280 million.  
  • Only a 20% reduction in drug-resistant infections would save $3.2 – $5.2 billion each year
    A 20% reduction in drug-resistant infections would save between 5.7 and 11.3 million additional hospital days and between $3.2 and $5.2 billion in healthcare costs, each year.  
  • Negative value of antibiotics to drug companies
    The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.